LLY · News · 20261001N
Revenue Performance and Mix
ELI LILLY & Co · 2026-10-01 · Importance 64 · Surprise 56 · Contradicted
Eli Lilly’s second-quarter revenue increased 47.70% year over year to $22.97 billion. The reported growth was driven by continued strength in obesity and diabetes treatments, including Mounjaro and Zepbound. Quarterly earnings per share exceeded consensus estimates.
Key facts
- Eli Lilly was the most active acquirer in Q3, striking two deals in Q3 and bringing its year-to-date total to 11 deals worth $31.7 billion. source
- Eli Lilly's second-quarter revenue surged by 47.70 percent to USD 22.97 billion. source
- Eli Lilly reported earnings per share that exceeded consensus estimates (as stated in the report on second-quarter results). source
- Eli Lilly and Company stock fell 1.18 percent at Lang & Schwarz following the Foundayo presentation. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +32.3% | Eli Lilly's second-quarter revenue surged by 47.70 percent to USD 22.97 billion. |
| assets | positive | committed | +18.9% | Eli Lilly was the most active acquirer in Q3, striking two deals in Q3 and bringing its year-to-date total to 11 deals worth $31.7 billion. |